SG10201404000RA - Methods and compositions for treating thyroid-related medical conditions with reduced folates - Google Patents

Methods and compositions for treating thyroid-related medical conditions with reduced folates

Info

Publication number
SG10201404000RA
SG10201404000RA SG10201404000RA SG10201404000RA SG10201404000RA SG 10201404000R A SG10201404000R A SG 10201404000RA SG 10201404000R A SG10201404000R A SG 10201404000RA SG 10201404000R A SG10201404000R A SG 10201404000RA SG 10201404000R A SG10201404000R A SG 10201404000RA
Authority
SG
Singapore
Prior art keywords
compositions
methods
medical conditions
related medical
treating thyroid
Prior art date
Application number
SG10201404000RA
Other languages
English (en)
Inventor
Linzy O Scott Iii
Original Assignee
Linzy O Scott Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Linzy O Scott Iii filed Critical Linzy O Scott Iii
Publication of SG10201404000RA publication Critical patent/SG10201404000RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG10201404000RA 2009-07-10 2010-07-09 Methods and compositions for treating thyroid-related medical conditions with reduced folates SG10201404000RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27061509P 2009-07-10 2009-07-10
US27074109P 2009-07-13 2009-07-13

Publications (1)

Publication Number Publication Date
SG10201404000RA true SG10201404000RA (en) 2014-10-30

Family

ID=43427658

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201404000RA SG10201404000RA (en) 2009-07-10 2010-07-09 Methods and compositions for treating thyroid-related medical conditions with reduced folates
SG2012002069A SG177613A1 (en) 2009-07-10 2010-07-09 Methods and compositions for treating thyroid-related medical conditions with reduced folates

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012002069A SG177613A1 (en) 2009-07-10 2010-07-09 Methods and compositions for treating thyroid-related medical conditions with reduced folates

Country Status (27)

Country Link
US (13) US8343974B2 (zh)
EP (2) EP3053583B1 (zh)
JP (6) JP5940448B2 (zh)
KR (1) KR101850558B1 (zh)
CN (2) CN102639009B (zh)
AP (1) AP2012006124A0 (zh)
AU (1) AU2010271178B2 (zh)
BR (1) BR112012000614B1 (zh)
CA (2) CA2804265C (zh)
DK (1) DK2451299T3 (zh)
EA (1) EA201270160A1 (zh)
ES (1) ES2569238T3 (zh)
HK (1) HK1174798A1 (zh)
HR (1) HRP20160406T1 (zh)
HU (1) HUE027341T2 (zh)
IL (3) IL304064A (zh)
IN (1) IN2012DN01286A (zh)
MX (2) MX350564B (zh)
MY (2) MY189270A (zh)
NZ (1) NZ598171A (zh)
PH (1) PH12019500495A1 (zh)
PL (1) PL2451299T3 (zh)
SG (2) SG10201404000RA (zh)
SI (1) SI2451299T1 (zh)
SM (1) SMT201600110B (zh)
WO (1) WO2011006147A1 (zh)
ZA (2) ZA201201002B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304064A (en) 2009-07-10 2023-08-01 O Scott Linzy Iii Methods and compositions for the treatment of diseases related to the thyroid gland, with a reduced amount of folates
WO2014143984A1 (en) * 2013-03-15 2014-09-18 Jarrow Formulas, Inc. Methods of producing nutritional supplements using mushrooms from the species poria cocos or flammulina velutipes
US20160053281A1 (en) * 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
CN103705497B (zh) * 2013-12-11 2015-04-01 武汉威立得生物医药有限公司 碘塞罗宁在制备治疗或预防流感病毒感染的药物中的应用
JP6424078B2 (ja) * 2014-02-13 2018-11-14 山洋電気株式会社 ステータ、ステータの製造方法、およびモータ
CN108992458A (zh) * 2018-06-12 2018-12-14 中国人民解放军第四军医大学 维生素b12用于制备预防和/或治疗术后认知功能障碍药物的应用
CA3175608A1 (en) * 2020-04-22 2021-10-28 Linzy O. Scott, Iii Treatment of conditions associated with thyroid hormone
WO2022208216A1 (en) * 2021-03-31 2022-10-06 Boggarapu, Shravya An oral liquid formulation of metformin, teneligliptin, vitamin b12, atorvastatin and levothyroxine for diabetes

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4205126A (en) * 1978-01-01 1980-05-27 Cartaya Oscar A Serum-free cell culture media
US5563126A (en) 1986-11-20 1996-10-08 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
IT1229517B (it) 1989-01-31 1991-09-03 Bioresearch Spa Impiego di acido 5-metiltetraidrofolico, di acido 5 formiltetraidrofolico, e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato adatte ad essere impiegate nella terapia dei disordini depressivi e composizioni farmaceutiche relative.
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5591709A (en) 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US5795873A (en) 1992-12-29 1998-08-18 Metabolite Laboratories, Inc. Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6
US6207651B1 (en) 1996-08-02 2001-03-27 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
US6455288B1 (en) 1993-04-08 2002-09-24 Dade Behring Marburg Gmbh Homogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases
CH686369A5 (de) 1994-05-09 1996-03-15 Eprova Ag Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure.
US5681561A (en) 1995-06-07 1997-10-28 Life Medical Sciences, Inc. Compositions and methods for improving autologous fat grafting
WO1997027764A1 (en) 1996-01-31 1997-08-07 South Alabama Medical Science Foundation Food and vitamin preparations containing the natural isomer of reduced folates
CH693255A5 (de) 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
US6200950B1 (en) 1998-02-18 2001-03-13 Nestec S.A. Calorically dense nutritional composition
US6153582A (en) 1998-11-05 2000-11-28 Bausch & Lomb Surgical, Inc. Defined serumfree medical solution for ophthalmology
CA2702148C (en) 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
WO2000042048A1 (en) 1999-01-19 2000-07-20 Leif Robert C A reagent system and method for increasing the luminescence of lanthanide(iii) macrocyclic complexes
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU5844799A (en) * 1999-04-08 2000-11-14 Airudin S. Khan Composition, containing sublimed sulphur, for altering plasma homodyst(e) levelsin humans
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US20020042096A1 (en) 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
WO2002074246A2 (en) 2001-03-20 2002-09-26 New Century Pharmaceuticals, Inc. Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds
US6506413B1 (en) 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
AU2002322275A1 (en) 2001-06-20 2003-01-08 Mayo Foundation For Medical Education And Research Adenosyl-cobalamin fortified compositions
US6660293B2 (en) 2001-06-29 2003-12-09 Everett Laboratories, Inc. Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects
US20030195253A1 (en) 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
WO2003068223A1 (en) 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
US7074426B2 (en) 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
WO2003105561A2 (en) 2002-06-12 2003-12-24 Surromed, Inc. Method and devices for diagnosing and treating choroid plexus failure
AU2003300776A1 (en) 2002-09-09 2004-05-25 Omeros Corporation G protein coupled receptors and uses thereof
KR20050065587A (ko) 2002-10-08 2005-06-29 이뮤노메딕스, 인코오포레이티드 항체 치료법
WO2004056311A2 (en) 2002-12-17 2004-07-08 Massachusetts Institute Of Technology Stimuli-responsive systems for controlled drug delivery
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US7354590B2 (en) 2003-04-09 2008-04-08 Jarrow Formulas, Inc. Methods of producing edible fungi containing activated folates and nutritional supplements containing activated folates
US7517342B2 (en) 2003-04-29 2009-04-14 Boston Scientific Scimed, Inc. Polymer coated device for electrically medicated drug delivery
US20050031544A1 (en) 2003-08-07 2005-02-10 Njemanze Philip Chidi Receptor mediated nanoscale copolymer assemblies for diagnostic imaging and therapeutic management of hyperlipidemia and infectious diseases
EP2311448A1 (en) 2003-12-24 2011-04-20 N.V. Nutricia Compositions comprising pantothenic acid or derivatives thereof and their use for stimulating appetite
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
WO2005110994A2 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
US20100087546A1 (en) 2005-04-20 2010-04-08 Biogenic Innovations, Llc Use of dimethyl sulfone (msm) to reduce homocysteine levels
US20060252049A1 (en) 2005-05-04 2006-11-09 Shuler Richard O Growth-promoting and immunizing subcutaneous implant
WO2006119589A2 (en) 2005-05-11 2006-11-16 Ramaekers, Vincent Prevention and therapy of cerebral folate deficiency
CN101203221B (zh) * 2005-06-21 2012-03-21 南阿拉巴马医学科学基金会 用于防御辐射损伤的方法和含有天然叶酸的组合物
RU2005128993A (ru) 2005-09-08 2007-03-20 Общество С Ограниченной Ответственностью Исследовательский Центр "Комкон" (Ru) Средство для коррекции стресс-индуцируемых нейромедиаторных, нейроэндокринных и метаболических нарушений, а также способ профилактики и лечения сопутствующих им паталогических состояний
CN103271083B (zh) 2005-10-07 2017-08-11 阿拉巴马大学 多功能离子液体组合物
US20070243132A1 (en) 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
WO2007117657A2 (en) 2006-04-07 2007-10-18 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US20090088404A1 (en) 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
EP2232013A1 (en) 2007-12-17 2010-09-29 Lux Innovate Limited Compositions and methods for monitoring flow through fluid conducting and containment systems
IL304064A (en) * 2009-07-10 2023-08-01 O Scott Linzy Iii Methods and compositions for the treatment of diseases related to the thyroid gland, with a reduced amount of folates

Also Published As

Publication number Publication date
US20170319589A1 (en) 2017-11-09
EP2451299A4 (en) 2012-12-19
BR112012000614A2 (pt) 2015-09-15
EP2451299B1 (en) 2016-04-06
US20210252002A1 (en) 2021-08-19
CN105476997A (zh) 2016-04-13
US20140030359A1 (en) 2014-01-30
IL304064A (en) 2023-08-01
CA2804265A1 (en) 2011-02-13
KR101850558B1 (ko) 2018-04-19
MY181956A (en) 2021-01-15
IL256966A (en) 2018-03-29
AU2010271178A1 (en) 2012-03-08
MY189270A (en) 2022-01-31
US20160158237A1 (en) 2016-06-09
SMT201600110B (it) 2016-07-01
US8343974B2 (en) 2013-01-01
JP2012532891A (ja) 2012-12-20
HK1174798A1 (zh) 2013-06-21
CA2804265C (en) 2019-02-19
ZA201201002B (en) 2013-05-29
HRP20160406T1 (hr) 2016-05-20
BR112012000614A8 (pt) 2018-06-12
SI2451299T1 (sl) 2016-10-28
NZ598171A (en) 2014-11-28
JP2019089858A (ja) 2019-06-13
CN105476997B (zh) 2019-06-21
US20210000836A1 (en) 2021-01-07
MX2012000535A (es) 2012-03-29
MX350564B (es) 2017-09-11
IL256966B2 (en) 2023-12-01
PL2451299T3 (pl) 2016-09-30
KR20120045010A (ko) 2012-05-08
US20200163969A1 (en) 2020-05-28
US20190060318A1 (en) 2019-02-28
ZA201301167B (en) 2014-12-23
JP2023068107A (ja) 2023-05-16
WO2011006147A1 (en) 2011-01-13
JP2016047840A (ja) 2016-04-07
JP5940448B2 (ja) 2016-06-29
ES2569238T3 (es) 2016-05-09
US8575171B2 (en) 2013-11-05
CN102639009A (zh) 2012-08-15
US20220354853A1 (en) 2022-11-10
DK2451299T3 (en) 2016-05-30
AU2010271178B2 (en) 2015-10-22
JP2021091739A (ja) 2021-06-17
EP3053583B1 (en) 2020-10-14
JP2017186383A (ja) 2017-10-12
US20190307756A1 (en) 2019-10-10
US20110008464A1 (en) 2011-01-13
US20130089623A1 (en) 2013-04-11
US20230201204A1 (en) 2023-06-29
AP2012006124A0 (en) 2012-02-29
PH12019500495A1 (en) 2020-06-15
CA3031481A1 (en) 2011-02-13
BR112012000614B1 (pt) 2022-05-24
CN102639009B (zh) 2016-01-20
US9248130B2 (en) 2016-02-02
HUE027341T2 (en) 2016-09-28
EA201270160A1 (ru) 2012-07-30
SG177613A1 (en) 2012-03-29
US20180185373A1 (en) 2018-07-05
CA3031481C (en) 2021-03-16
IL256966B1 (en) 2023-08-01
EP2451299A1 (en) 2012-05-16
IL217401A0 (en) 2012-02-29
IN2012DN01286A (zh) 2015-05-15
EP3053583A1 (en) 2016-08-10

Similar Documents

Publication Publication Date Title
HK1247821A1 (zh) 用於預防或治療眼科病症的方法和組合物
IL256966A (en) Methods and compositions for the treatment of diseases related to the thyroid gland, with a reduced amount of folates
IL239918A0 (en) Preparations for the treatment of colitis
EP2655334A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
IL218987A0 (en) Methods and compositions for treating cancer
EP2542060A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES
EP2608778A4 (en) COMPOSITIONS AND METHODS FOR TREATING BONE ANOMALIES
EP2497482A4 (en) COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF INFLUENZA AVIRUSED INDUCED DISEASES
EP2504428A4 (en) METHOD AND COMPOSITIONS FOR TREATING OXALATE-MEDIATED SUFFERING
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
EP2419136A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
EP2411006A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS
IL215932A0 (en) Compositions and methods for treating burns
IL214349A0 (en) Compositions and methods for the treatment of cancer
EP2437738A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
HK1183766A1 (zh) 用於治療瘀傷的組合物和方法
EP2542057A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFAMOUS DISEASES
EP2456437A4 (en) COMBINATION THERAPY FOR TAUOPATHIES
EP2411031A4 (en) Methods and compositions for the treatment of cancer
EP2393506A4 (en) METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES
EP2427052A4 (en) METHODS AND COMPOSITIONS FOR USE IN THE TREATMENT OF OPHTHALMIC DISORDERS
EP2462131A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH BETA-AMYLOID